TREA

87777607 - ENGENSIS

Follow

Information

  • Trademark
  • 87777607
  • Serial Number
    87777607
  • Registration Number
    5694789
  • Filing Date
    January 31, 2018
    8 years ago
  • Registration Date
    March 12, 2019
    7 years ago
  • Transaction Date
    June 10, 2025
    a year ago
  • Status Date
    June 09, 2025
    a year ago
  • Published for Opposition Date
    October 02, 2018
    7 years ago
  • Location Date
    June 09, 2025
    a year ago
  • Status Code
    702
  • Current Location
    Historical data usage
    Employee Name
    FIRST, VIVIAN
  • Attorney Docket Number
    095318601029
    Attorney Name
    Daniel P. Mullarkey
  • Owners
Information
Mark Drawing Code
4
Mark Identification
ENGENSIS
Case File Statements
  • GS0051: Chemical reagents for use in veterinary genetic testing; reagents for use in medical genetic testing; diagnostic preparations for medical purposes for detecting mutation in prion genes; preparations for medical purposes for detecting mutation in prion genes; chemical preparations for pharmaceutical purposes, namely, for painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; drugs for medical purposes, namely, prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; pharmaceutical preparations for the treatment of painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; medicines for human purposes, namely, pharmaceutical preparations for the treatment of painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; pharmaceutical preparations for diagnosis of painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; ethical medicinal preparations, namely, pharmaceutical preparations for the treatment of painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; pharmaceutical preparations for the treatment of immune system related diseases and disorders; chemical preparations for use in medical DNA analysis; genetic treatment pharmaceutical preparations
  • GS0421: Pharmaceutical research and development; pharmaceutical research services; consultancy relating to pharmaceutical research and development; research and development of vaccines and medicines; scientific research in the fields of biomedicine; research and testing services in the fields of bacteriology and virology; drug discovery services; research and development in the pharmaceutical and biotechnology fields; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; consultancy in analysis of biology sequence processing for medical research purposes; consultancy in analysis of genomics for medical research purposes; scientific research in the fields of medicine, health and pharmacology; analysis of human serum for medical research; analysis of human tissues for medical research; blood analysis services
Case File Event Statements
  • 5/1/2018 - 8 years ago
    4 - ASSIGNED TO LIE Type: ALIE
  • 2/3/2018 - 8 years ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 2/9/2018 - 8 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 4/24/2018 - 8 years ago
    3 - TEAS VOLUNTARY AMENDMENT RECEIVED Type: PARI
  • 5/1/2018 - 8 years ago
    6 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 5/1/2018 - 8 years ago
    5 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 5/14/2018 - 8 years ago
    7 - ASSIGNED TO EXAMINER Type: DOCK
  • 5/14/2018 - 8 years ago
    8 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 5/14/2018 - 8 years ago
    10 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 5/14/2018 - 8 years ago
    9 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 8/23/2018 - 7 years ago
    11 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 8/23/2018 - 7 years ago
    13 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 8/23/2018 - 7 years ago
    12 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 8/24/2018 - 7 years ago
    14 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 10/2/2018 - 7 years ago
    16 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 12/21/2018 - 7 years ago
    19 - TEAS DELETE 1(B) BASIS RECEIVED Type: D1BR
  • 12/21/2018 - 7 years ago
    21 - NOTICE OF ALLOWANCE CANCELLED Type: IUCN
  • 9/12/2018 - 7 years ago
    15 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 10/2/2018 - 7 years ago
    17 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 11/27/2018 - 7 years ago
    18 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM
  • 2/5/2019 - 7 years ago
    20 - CASE ASSIGNED TO INTENT TO USE PARALEGAL Type: AITU
  • 2/5/2019 - 7 years ago
    22 - 1(B) BASIS DELETED; PROCEED TO REGISTRATION Type: DP1B
  • 3/12/2019 - 7 years ago
    23 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 5/10/2019 - 7 years ago
    24 - REVIEW OF CORRESPONDENCE COMPLETE - CERTIFICATE OF REG MAILED Type: CORV
  • 6/19/2019 - 7 years ago
    25 - AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Type: ASGN
  • 3/12/2024 - 2 years ago
    26 - COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED Type: REM1
  • 2/13/2025 - a year ago
    27 - TEAS SECTION 8 & 15 RECEIVED Type: E815
  • 6/9/2025 - a year ago
    28 - CASE ASSIGNED TO POST REGISTRATION PARALEGAL Type: APRE
  • 6/9/2025 - a year ago
    29 - REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. Type: C15A
  • 6/9/2025 - a year ago
    30 - NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED Type: NA85